Day: June 3, 2026

AvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026

WATERTOWN, Mass. and DRESDEN, Germany, June 2, 2026 /PRNewswire/ -- AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T...

Acclinate, HCN Global Unveil Strategic Partnership Expanding Clinical Research Access and Representation for Hispanic & Latino Communities

The partnership complements Acclinate's NOWINCLUDED community, creating new audience access and integrating HCN Global's networks into Acclinate's e-DICTâ„¢ platform.BIRMINGHAM, Ala.,...

error: Content is protected !!